These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 24558627)

  • 41. Equivalent Efficacy and Decreased Rate of Overcorrection in Patients With Syndrome of Inappropriate Secretion of Antidiuretic Hormone Given Very Low-Dose Tolvaptan.
    Hanna RM; Velez JC; Rastogi A; Nguyen MK; Kamgar MK; Moe K; Arman F; Hasnain H; Nobakht N; Selamet U; Kurtz I
    Kidney Med; 2020; 2(1):20-28. PubMed ID: 32734225
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Randomized, double blinded, placebo-controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH.
    Chen S; Zhao JJ; Tong NW; Guo XH; Qiu MC; Yang GY; Liu ZM; Ma JH; Zhang ZW; Gu F
    J Clin Pharmacol; 2014 Dec; 54(12):1362-7. PubMed ID: 24906029
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tolvaptan for the treatment of hyponatremia secondary to the syndrome of inappropriate antidiuretic hormone secretion.
    Gargani L; Schmidt PH; Gheorghiade M
    Expert Rev Cardiovasc Ther; 2011 Dec; 9(12):1505-13. PubMed ID: 22103869
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [From hyponatremia to tolvaptan].
    Cernaro V; Santoro D; Lacquaniti A; Montalto G; Buemi M
    G Ital Nefrol; 2014; 31(1):. PubMed ID: 24671837
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Current Management of Hyponatremia in Acute Heart Failure: A Report From the Hyponatremia Registry for Patients With Euvolemic and Hypervolemic Hyponatremia (HN Registry).
    Dunlap ME; Hauptman PJ; Amin AN; Chase SL; Chiodo JA; Chiong JR; Dasta JF
    J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28775063
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT-1 and SALT-2 trials.
    Gralla RJ; Ahmad F; Blais JD; Chiodo J; Zhou W; Glaser LA; Czerwiec FS
    Cancer Med; 2017 Apr; 6(4):723-729. PubMed ID: 28251822
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Vasopressin dysregulation and hyponatremia in hospitalized patients.
    Multz AS
    J Intensive Care Med; 2007; 22(4):216-23. PubMed ID: 17712057
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Vaptans and hyponatremia in critical patients.
    D'Auria D; Marinosci GZ; De Benedictis G; Piazza O
    Transl Med UniSa; 2012 May; 3():1-14. PubMed ID: 23905047
    [TBL] [Abstract][Full Text] [Related]  

  • 49. SIADH with Severe Hyponatremia in an Elderly Man with Herpes Zoster Infection: A Causal or Casual Association?
    Foppiani L
    Intern Med; 2018 Dec; 57(23):3393-3398. PubMed ID: 29984775
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recognition and treatment of hyponatremia in acutely ill hospitalized patients.
    Patel GP; Balk RA
    Clin Ther; 2007 Feb; 29(2):211-29. PubMed ID: 17472815
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Management of euvolemic hyponatremia attributed to SIADH in the hospital setting.
    Peri A; Giuliani C
    Minerva Endocrinol; 2014 Mar; 39(1):33-41. PubMed ID: 24513602
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
    Schrier RW; Gross P; Gheorghiade M; Berl T; Verbalis JG; Czerwiec FS; Orlandi C;
    N Engl J Med; 2006 Nov; 355(20):2099-112. PubMed ID: 17105757
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hyponatremia in Heart Failure: Pathogenesis and Management.
    Rodriguez M; Hernandez M; Cheungpasitporn W; Kashani KB; Riaz I; Rangaswami J; Herzog E; Guglin M; Krittanawong C
    Curr Cardiol Rev; 2019; 15(4):252-261. PubMed ID: 30843491
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hyponatremia, heart failure, and the role of tolvaptan.
    O'Connell JB; Alemayehu A
    Postgrad Med; 2012 Mar; 124(2):29-39. PubMed ID: 22437213
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Case Report: Long-Term Tolvaptan Treatment in a Child With SIADH and Suprasellar Arachnoid Cyst.
    Puma A; Brugnara M; Cavarzere P; Zaffanello M; Piacentini G; Gaudino R
    Front Pediatr; 2021; 9():684131. PubMed ID: 34336740
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Employment of vasopressin receptor antagonists in management of hyponatraemia and volume overload in some clinical conditions.
    Urso C; Brucculeri S; Caimi G
    J Clin Pharm Ther; 2015 Aug; 40(4):376-85. PubMed ID: 25924179
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vasopressin antagonism: potential impact on neurologic disease.
    Rabinstein AA
    Clin Neuropharmacol; 2006; 29(2):87-93. PubMed ID: 16614541
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A rapid and efficient way to manage hyponatremia in patients with SIADH and small cell lung cancer: treatment with tolvaptan.
    Petereit C; Zaba O; Teber I; Lüders H; Grohé C
    BMC Pulm Med; 2013 Aug; 13():55. PubMed ID: 23987478
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hyponatremia and the use of vasopressin receptor antagonists in critically ill patients.
    Lehrich RW; Greenberg A
    J Intensive Care Med; 2012; 27(4):207-18. PubMed ID: 21571754
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Vaptans: a promising therapy in the management of advanced cirrhosis.
    Ginès P
    J Hepatol; 2007 Jun; 46(6):1150-2. PubMed ID: 17445935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.